Coronavirus vaccine rises as UK company AstraZeneca says jab could give immunity for at least 12 months


The coronavirus vaccine could confer immunity for at least 12 months, UK firm AstraZeneca trial leader has revealed.

Sir Mene Pangalos, who is leading the lab effort alongside the University of Oxford, said he could even give two years of protection against the killer bug, in a “big step forward”.

⚠️ Read our live coronavirus blog for the latest news and updates

Company is pushing for vaccines to be approved by OctoberCrédits: Getty Images – Getty

The head of bio-pharmaceutical research and development told BBC Newscast: “Based on the precedents, along with other studies being carried out by the Oxford group, we hope that the immune response will last at least 12 months but, hopefully, closer to 24 or more. ”

“You get the flu shot every year, hope it lasts longer, but we don’t know, but we would like it to last at least 12 months.

“But given how contagious this virus is and how far it is spreading around the world, I think anything that can protect you from getting sick, from getting sick, from going to the hospital, I think it will be a big step forward for the world. ”

The company is working quickly to get the jab approved by October.

Based on tests, Sir Pangalos said the most effective way to get the right dose to build an immune response appears to be to receive two doses apart.

The immune response in those over 55 is still unclear, and it is still unclear whether the vaccine could be given to children and provide lifelong protection, such as the measles vaccination.

In addition to the 100 million doses of a vaccine being developed by the University of Oxford, the government has also obtained early access to 60 million doses of GlaxoSmithKline and Sanofi Pasteur.


If the vaccine candidate proves effective in human studies, the UK may be able to immunize priority groups – such as frontline health and social workers and vulnerable people – as early as the first half of 2021.

Human clinical studies of the vaccine will begin in September, followed by a phase 3 study in December 2020.

The government has now gained rapid access to four different types of vaccination and a total of 250 million doses.

Matt Hancock has previously said the best-case scenario is that a vaccine is available this year.

But the health secretary added that he would be “more likely” ready in 2021.

Kate Bingham, Chair of the Government Vaccine Task Force, said: “With this agreement with GSK and Sanofi, we can add another type of vaccine to the three types of vaccines we have already obtained.

“This diversity of vaccine types is important because we do not yet know which of the different vaccine types, if any, will prove to generate a safe and protective response to Covid-19. While this deal is great news, we must not be complacent or overly optimistic.

“The fact remains that we can never get a vaccine and if we do get one we have to be prepared that it is not a vaccine that prevents getting the virus, but rather a vaccine that reduces symptoms. “

Last week, the UK secured 90 million doses of a potential vaccine to ensure the British are on the front line for a vaccine.

This agreement is developed by an alliance between BioNtech and Pfizer as well as the company Valneva.

It comes as Boris Johnson warned him there are signs of a second wave sweeping through Europe.


Credit: AFP or licensors

Dr Sarah Jarvis congratulates the government on signing an agreement with pharmaceutical giants GlaxoSmithKline and Sanofi Pasteur for 60 million doses of a potential vaccine against covid-19


Please enter your comment!
Please enter your name here